

# Evidence of Syntaxin 1A Involvement in Migraine Susceptibility

## A Portuguese Study

Carolina Lemos, PhD; José Pereira-Monteiro, MD, PhD; Denisa Mendonça, PhD; Eliana Marisa Ramos, BSc; José Barros, MD; Jorge Sequeiros, MD, PhD; Isabel Alonso, PhD; Alda Sousa, PhD

**Objective:** To confirm syntaxin 1A as a risk factor for migraine, given that syntaxin 1A interacts with several factors in migraine pathophysiology.

**Design:** Case-control approach.

**Setting:** An outpatient clinic.

**Participants:** In a sample of 188 migraineurs (111 without aura and 77 with aura) and 287 migraine-free controls, 3 tagging SNPs of *STX1A* (rs3793243, rs941298, and rs6951030) were analyzed. A backward stepwise multiple logistic regression was performed. Allelic and haplotypic frequencies were compared between cases and controls.

**Results:** We found that rs941298 and rs6951030 were risk factors for migraines. In particular, the TT genotype of rs941298 is associated with an increased risk of both migraine in general and migraine without aura; the

GG and GT genotypes for rs6951030 are also associated with migraine, while the GT genotype of rs6951030 was found to be significant in the migraine without aura group. The single-nucleotide polymorphism rs3793243 did not show any significant association. In the haplotype-based analysis, we found an underrepresentation of the T-C-T haplotype (rs3793243-rs941298-rs6951030) in the global sample and in migraine without aura group. We found an enrichment of the G allele of rs6951030 for female migraineurs only.

**Conclusions:** We confirmed the involvement of syntaxin 1A in migraine susceptibility regarding rs941298. In addition, we found rs6951030 to also be associated in Portuguese migraine patients. Sex differences should be further explored to disentangle a possible sex susceptibility in syntaxin 1A.

*Arch Neurol.* 2010;67(4):422-427

**Author Affiliations:** Instituto Ciências Biomédicas Abel Salazar (Drs Lemos, Pereira-Monteiro, Mendonça, Barros, Sequeiros, and Sousa and Ms Ramos), and Instituto Biologia Molecular Celular (Drs Lemos, Pereira-Monteiro, Sequeiros, Alonso, and Sousa, and Ms Ramos), Universidade do Porto, Porto, Portugal; and Serviço de Neurologia, Centro Hospitalar do Porto—Hospital de Santo António, Porto (Drs Pereira-Monteiro and Barros).

**M**IGRAINE IS A COMMON neurological disorder, affecting about 15% of the general population.<sup>1,2</sup> Familial aggregation studies have shown that migraine is essentially caused by genetic factors, with multiple genes contributing to its liability, in addition to environmental factors.<sup>3</sup> We have also confirmed the presence of a genetic component in migraine with and without aura in a Portuguese population.<sup>4</sup>

Although some loci for migraine with and without aura have been proposed, the genes involved have not yet been identified. Several candidate genes have been studied, with contradictory results.<sup>3</sup> Some evidence supports that the neurotransmitter system is also involved in migraine pathophysiology.<sup>5</sup> Serotonin plays a role in pain modulation, and serotonin agonists are an effective therapeutic approach to migraine.<sup>6</sup> The serotonin transporter is in-

involved in serotonin reuptake and is a target for serotonin reuptake inhibitors.<sup>7</sup>

Syntaxin 1A is a presynaptic plasma membrane protein of the syntaxin family that, in conjunction with other proteins, compose the soluble *N*-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) complex, which is crucial for the regulation of the presynaptic release of neurotransmitters. Syntaxin 1A, encoded by the *STX1A* gene (OMIM 186590), is one of the regulatory proteins of the expression and subcellular localization of the serotonin transporter.<sup>7</sup> Furthermore, syntaxin 1A binds to the neuronal  $\gamma$ -aminobutyric acid (GABA) transporter, inhibiting its reuptake.  $\gamma$ -Aminobutyric acid is the main inhibitory neurotransmitter in the brain, and some GABA-receptor agonists are used in migraine prophylaxis.<sup>8</sup>

Nitric oxide is also involved in the formation of the SNARE complex and in the interaction of syntaxin 1A and the GABA transporter.<sup>9</sup> Nitric oxide has also been as-

sociated with the nociception mechanism and consequently with migraine pathophysiology.<sup>10</sup>

The gene encoding the  $\alpha_{1A}$  subunit of a voltage-dependent calcium channel (*CACNA1A*) is involved in a rare form of migraine with aura, familial hemiplegic migraine (FHM) type 1. It has been shown that the association of the SNARE proteins with presynaptic  $Ca^{2+}$  channels, including *CACNA1A*, is essential for neurotransmitter release.<sup>11</sup>

Recently, syntaxin 1A was proposed as a risk factor for migraine.<sup>12</sup> The aim of this study was to confirm the involvement of syntaxin 1A in migraine's susceptibility, using a case-control approach, given that syntaxin 1A interacts with several factors of migraine pathophysiology.

## METHODS

### SUBJECTS

One hundred eighty-eight unrelated patients with migraine (111 without aura, 77 with aura), from the neurology outpatient clinic, at Hospital de Santo António, Porto, Portugal, were sequentially enrolled in this study. Patients with FHM were excluded; migraineurs with cooccurrence of migraine with and without aura were included in the group with aura. Control subjects ( $n=287$ ), with no history of migraine, were ascertained among healthy blood donors and from the obstetrics and gynecology department of Hospital de Santo António. Women with menstrual headaches were excluded from the control group. Controls were from the same ethnic and geographical origin as the cases (northern region of the country) and were age-matched. A diagnostic interview was performed in cases and controls, based on the operational criteria of the International Headache Society, using the same structured questionnaire. The first edition of the International Headache Society criteria<sup>13</sup> was used before 2004; when revising the diagnosis using the second edition,<sup>14</sup> we found no differences in patients' diagnosis (data not shown). Participants gave their written informed consent, and the ethics committee of the Hospital de Santo António approved the project.

### SELECTION OF SNPs AND GENOTYPING

Genomic DNA was isolated from peripheral blood, using a standard salting out method<sup>15</sup> or from saliva, using ORAGENE kits according to the manufacturer's instructions (DNA Genotek Inc). Single-nucleotide polymorphisms (SNPs) were selected based on a data registry from the International HapMap Project; tagging SNPs were selected using Haploview 4.1, at an  $r^2$  threshold of 0.80, with a minor allele frequency greater than 0.10, by an aggressive tagging approach.<sup>16</sup> Tagging SNPs included rs3793243 (located in chromosome 7: 72 759 283), rs941298 (72 763 199), and rs6951030 (72 771 177, according to the Ensembl database).

In the first stage, allelic discrimination was performed using molecular beacons and real-time polymerase chain reactions (PCRs) (iQ5 Real-Time PCR Detection System, Bio-Rad Laboratories). A few discrepancies were found, however, after sequencing (to confirm uncertain genotypes): real-time PCR did not prove to be a reliable method for allelic discrimination with these SNPs. Therefore, we chose to sequence all samples for rs3793243 and rs941298, while for rs6951030 we used a restriction-enzyme analysis.

All SNPs were PCR-amplified using HotStar Taq Master Mix Kit (Qiagen) according to the manufacturer's instructions

(primer sequences are available from the authors on request). Sequencing was performed using the Big Dye Terminator Cycle Sequencing, version 1.1, Ready Reaction (Applied Biosystems), according to the manufacturer's instructions, and samples were loaded in an ABI-PRISM 3130 XL genetic analyzer (Applied Biosystems). Restriction enzyme analysis was performed with *BsrI* after PCR amplification, and electrophoresis was performed on digestion products in a 2% agarose gel, stained with ethidium bromide.

## STATISTICAL ANALYSIS

Power estimations were performed using the Genetic Power Calculator (<http://pnuu.mgh.harvard.edu/~purcell/gpc/>). Analysis of Hardy-Weinberg equilibrium was also performed.<sup>17</sup> Demographic data of patients and controls were compared using a  $\chi^2$  test for categorical variables. To compare SNP allele frequencies between cases and controls, the  $\chi^2$  test was used, and odds ratios (ORs) were estimated with 95% confidence intervals (CIs). Significance was set at  $\alpha=.05$ .

A backward stepwise multiple logistic regression was performed (with the most frequent homozygote as the reference category) to evaluate the association between the SNPs' genotypes and the occurrence of migraine, by including the 3 SNPs and sex in the initial model. We also evaluated the role of *STX1A* in the migraine subtypes. All analyses were performed in the total sample, as well as in the subsets of migraine with and without aura. Significance was set at  $\alpha=.016$  (considering 3 logistic regressions) using a Bonferroni correction to correct for multiple comparisons.

These analyses were performed using SPSS, version 16.0. Haplotype frequencies were compared between cases and controls, using Haploview 4.1 with all parameters set at the default values.<sup>16</sup> Haplotypes were estimated, using an accelerated expectation-maximization algorithm similar to the partition-ligation expectation-maximization algorithm described by Qin et al,<sup>18</sup> and case-control counts were obtained by summing the fractional likelihoods of each individual for each haplotype.<sup>16</sup> Frequencies of analyzed haplotypes were above 1%, according to the Haploview threshold; to correct for multiple comparisons, regarding estimation of allelic and haplotype frequencies, we used 10 000 permutations. In the pooled sample, a  $\chi^2$  and OR were estimated, assuming  $\alpha=.05$ , to compare allelic and genotypic frequencies between cases and controls.

## RESULTS


We analyzed a sample of 188 unrelated migraineurs and 287 age-matched controls (case to control ratio of 1:1.5). With this sample, we had a power of 64% to detect association (for a nominal  $\alpha=.05$ ), assuming a high-risk allele frequency of 0.1, a relative risk for AA genotype of 2.25, and 1.5 for Aa genotype. A migraine prevalence of 16% had been previously estimated in a Portuguese population.<sup>19,20</sup>

Demographic and clinical data can be found in **Table 1**. A family history of migraine was present in 87% of the cases. No significant differences were found regarding sex between patients and controls ( $P>.05$ ).

Both case and control groups were in Hardy-Weinberg equilibrium for the 3 SNPs studied. The correlation between the 3 SNPs was small, denoting the weak linkage disequilibrium (LD) between them according to the LD plot (**Figure**). In our sample, the 3 SNPs were also in weak LD (data not shown).

**Table 1. Demographic and Clinical Data of Patients With Migraine and Controls**

Characteristic	No.	
	Patients With Migraine (n=188)	Controls (n=287)
Migraine with aura	77	
Migraine without aura	111	
Sex, F/M	153/35	217/70
Age at observation, mean (SD), y	36.14 (12.84)	36.42 (12.35)
Age at onset, mean (SD), y	17.67 (8.15)	
Family history of migraine, %	87	



**Figure.** Linkage disequilibrium plot of single-nucleotide polymorphisms within *STX1A* (HaploView 4.1);  $r^2$  values are given within each square. kb indicates kilobases.

Regarding allele frequencies (**Table 2**), we found an enrichment of the G allele of rs6951030 among migraineurs (OR, 1.52; 95% CI, 1.12-2.06) as well as in the group without and the group with aura (without aura, OR, 1.48; 95% CI, 1.04-2.12; with aura, OR, 1.58; 95% CI, 1.06-2.36); however, after permutation-based correction, the result for migraine without aura and with aura did not reach significance. We found an enrichment of the T allele for rs941298 in patients with migraines without aura (OR, 1.44; 95% CI, 1.04-1.99); however, this finding did not hold after permutation-based correction. No significant differences were found for this SNP in the other groups. There were no significant differences in the allele frequencies between cases and controls, regarding rs3793243, for any of the groups.

Additionally, we stratified these data by sex and found an enrichment of the G allele of rs6951030 only in female migraineurs (OR, 1.56; 95% CI: 1.11-2.20), but this was not significant after permutation-based correction. In men, no significant results were found (not shown).

Genotypic frequencies of the SNPs are shown in **Table 3**. Results from the backward stepwise multiple logistic regression, with the 3 SNPs and sex included in the initial model, are shown in **Table 4**. Values for each SNP were adjusted for the remaining significant variables in the model. For the migraine sample, the TT genotype of rs941298 showed an increased risk in patients with migraine (OR, 2.22; 95% CI, 1.19-4.12), significant after Bonferroni correction; the GT and GG genotypes of rs6951030 were also associated with an increased risk of migraine (GT, OR, 1.68; 95% CI, 1.13-2.51; GG, OR, 3.27; 95% CI, 1.35-7.88), also significant after Bonferroni correction. Interestingly, the TT genotype of rs941298 also showed an increased risk of migraine without aura (OR, 3.11; 95% CI, 1.52-6.33); and heterozygosity for rs6951030 was associated with an increased risk of migraine without aura (OR, 1.85; 95% CI, 1.14-2.99), withstanding Bonferroni correction. An OR higher than 2 (OR, 3.01; 95% CI, 1.05-8.64) was found for the GG genotype, which may indicate that this genotype is also a risk factor for migraine without aura (though not statistically significant after Bonferroni correction), similar to what was found in the sample of migraine with aura (OR, 3.20; 95% CI, 1.14-8.92). The SNP rs3793243 did not show any significant association.

In a haplotype-based analysis (**Table 5**), C-C-G was more frequent in migraineurs than in controls (OR, 1.40, but it did not withstand permutation-based correction). Also, T-C-T was less frequent in migraineurs and in patients with migraine without aura than in controls, suggesting a possible protective role of the T allele of rs6951030 (migraine sample, OR, 0.54;  $P = .03$ ; after a permutation-based correction, OR, 0.43;  $P = .02$ ). Interestingly, we found an increased risk for the T-T-T haplotype in those with migraines without aura, showing that the T allele of rs941298 might confer an increased risk of migraines without aura (OR, 1.44), but this was not significant after permutation-based correction.

We also stratified the haplotype-based analysis regarding sex and found a protective role for T-C-T in women (nonsignificant after multiple-testing correction). In men, we did not find any differences in haplotype frequencies between cases and controls (data not shown).

Patients with cooccurrence of migraines with and without aura were first included in the sample with aura. In a further analysis, we decided to exclude these patients from the analysis, and the results we found were similar regarding the involvement of the 3 SNPs in migraine with aura (data not shown).

Additionally, we performed a pooled analysis of our data and those published by Corominas et al,<sup>12</sup> excluding the Catalanian patients with hemiplegic migraine. We found a significant association between rs941298 and the total sample and the group with migraine without aura (not shown). With allele frequencies of rs941298 pooled together, risk was significantly increased for the migraine sample and in patients with migraine without aura who have the T allele (not shown). For rs6951030, we did not find any significant results after pooling.

We performed a PupaSuite database search<sup>21</sup> to assess a putative functional role of these SNPs: (1) rs6951030 is located in a conserved region, which may indicate it

**Table 2. Allele Frequencies of SNPs Studied in Patients With Migraine and Controls**

Participant	Alleles, No. (%)			$\chi^2$	OR (95% CI)	P Value	P Value, After Permutation
	T	C	G				
<b>rs3793243</b>							
All patients with migraine	159 (42.3)	217 (57.7)		0.00	1.00 (0.77-1.30)	.99	1.00
Without aura	100 (45.0)	122 (55.0)		0.48	1.12 (0.82-1.52)	.48	.97
With aura	59 (38.3)	95 (61.7)		0.81	0.85 (0.59-1.22)	.37	.89
Controls	243 (42.3)	331 (57.7)					
<b>rs941298</b>							
All patients with migraine	130 (34.6)	246 (65.4)		2.05	1.22 (0.93-1.62)	.15	.56
Without aura	85 (38.3)	137 (61.7)		4.85	1.44 (1.04-1.99)	.03 <sup>a</sup>	.13
With aura	45 (29.2)	109 (70.8)		0.05	0.96 (0.65-1.41)	.82	1.00
Controls	173 (30.1)	401 (69.9)					
<b>rs6951030</b>							
All patients with migraine	269 (71.5)		107 (28.5)	7.48	1.52 (1.12-2.06)	.006 <sup>a</sup>	.03 <sup>a</sup>
Without aura	160 (72.1)		62 (27.9)	4.72	1.48 (1.04-2.12)	.03 <sup>a</sup>	.14
With aura	109 (70.8)		45 (29.2)	5.01	1.58 (1.06-2.36)	.02 <sup>a</sup>	.12
Controls	455 (79.3)		119 (20.7)				

Abbreviations: CI, confidence interval; OR, odds ratio; SNP, single-nucleotide polymorphism.  
<sup>a</sup>Nominal and corrected; significant value.

is important for gene regulation; and (2) rs941298 is located in a triplex sequence and may affect its structure formation, altering regulation. Additionally, we assessed if there were any regulatory SNPs in LD with rs6951030 and rs941298. The SNP rs6951030 is not in LD with any other SNP genotyped in the HapMap project. We found that rs867500 (in LD with rs941298) is located in an exonic-splicing enhancer motif.

**COMMENT**

We analyzed the role of *STX1A* in migraine susceptibility and, more specifically, in migraine subtypes with and without aura. Our findings confirm the involvement of *STX1A* as a risk factor for migraine. The intronic variants rs941298 and rs6951030 may play a role on migraine and, particularly, in migraine without aura. Additionally, we cannot exclude the effect of rs6951030 in migraine with aura, because the homozygous state of GG results in an OR above 2; however, the result was not significant after Bonferroni correction.

The haplotype analysis also supports the involvement of the rs6951030 G allele in migraine susceptibility and a protective role for the T allele both for migraine and migraine without aura. With this we also confirmed the increased risk conferred by the rs941298 T allele. Comparing allele frequencies, we found an association of rs6951030 with migraine and migraine subtypes, while for rs941298 only an association with migraine without aura was found; results for rs3793243 were not significant.

We found a sex-related effect in rs6951030, because only the female group showed enrichment of the G allele. This may be due to hormonal effects mediated by epigenetic modifications.<sup>22</sup> We cannot exclude, however, that the nonincreased risk in men is due to its small size in our sample. It would be important to explore this in larger samples to disentangle a possible sex susceptibility regarding syntaxin 1A.

**Table 3. Genotype Frequencies by Single-Nucleotide Polymorphism in Patients With Migraine and Controls**

Genotype	No. (%)			
	All Patients With Migraine (n=188)	Patients With Migraine		Controls (n=287)
		Without Aura (n=111)	With Aura (n=77)	
rs3793243				
CC	67 (35.6)	37 (33.3)	30 (39.0)	89 (31.0)
TC	83 (44.2)	48 (43.2)	35 (45.5)	153 (53.3)
TT	38 (20.2)	26 (23.4)	12 (15.6)	45 (15.7)
rs941298				
CC	28 (14.9)	46 (41.4)	40 (51.9)	28 (9.8)
CT	74 (39.4)	45 (40.5)	29 (37.7)	117 (40.8)
TT	86 (45.7)	20 (18.0)	8 (10.4)	142 (49.5)
rs6951030				
TT	95 (50.5)	56 (50.5)	39 (50.6)	178 (62.0)
TG	79 (42.0)	48 (43.2)	31 (40.3)	99 (34.5)
GG	14 (7.5)	7 (6.3)	7 (9.1)	10 (3.5)

In the recent study from Catalonia, Spain,<sup>12</sup> significant differences were found between cases and controls, both in allele and genotype frequencies of rs941298. The T allele was overrepresented in cases, either with or without aura. In our study, we also found an effect of the TT genotype in the global sample and in the subset of migraine without aura. In contrast to our results, no association with rs6951030 was found in the Catalanian study.

Although our study replicates the involvement of *STX1A* in migraine susceptibility, different variants were associated. Our data suggest a stronger effect of this gene in migraine without aura regarding rs6951030 and rs941298.

The difference between our results and those from Catalonia<sup>12</sup> regarding rs6951030 may be due to allele fre-

**Table 4. Results From the Backward Stepwise Multiple Logistic Regression**

Genotype	Migraine		Migraine Without Aura		Migraine With Aura	
	OR (95% CI)	P Value	OR (95% CI)	P Value	OR (95% CI)	P Value
rs3793243		.25		.30		.67
CC <sup>a</sup>	1 [Reference]		1 [Reference]		1 [Reference]	
CT	0.66 (0.39-1.11)	.12	0.62 (0.32-1.19)	.15	0.80 (0.44-1.42)	.44
TT	0.86 (0.38-1.94)	.71	0.88 (0.33-2.34)	.80	1.02 (0.46-2.29)	.96
rs941298		.04		.008 <sup>b</sup>		.85
CC <sup>a</sup>	1 [Reference]		1 [Reference]		1 [Reference]	
CT	1.16 (0.77-1.75)	.48	1.32 (0.80-2.18)	.27	1.16 (0.59-2.26)	.67
TT	2.22 (1.19-4.12)	.01 <sup>b</sup>	3.11 (1.52-6.33)	.002 <sup>b</sup>	1.36 (0.42-4.45)	.61
rs6951030		.004 <sup>b</sup>		.02 <sup>b</sup>		.06
TT <sup>a</sup>	1 [Reference]		1 [Reference]		1 [Reference]	
GT	1.68 (1.13-2.51)	.01 <sup>b</sup>	1.85 (1.14-2.99)	.01 <sup>b</sup>	1.43 (0.84-2.43)	.19
GG	3.27 (1.35-7.88)	.008 <sup>b</sup>	3.01 (1.05-8.64)	.04	3.20 (1.14-8.92)	.03

Abbreviations: CI, confidence interval; OR, odds ratio.

<sup>a</sup>After Bonferroni correction, significance level was set at  $\alpha = .016$ .

<sup>b</sup>Significant value.

**Table 5. Results From the Haplotype Analysis**

Haplotype <sup>a</sup>	Cases		Controls		OR (95% CI)	$\chi^2$	P Value <sup>b</sup>	P Value, After Permutation
	Carriers	Noncarriers	Carriers	Noncarriers				
All patients								
C-C-G	89.9	286.1	105.4	468.6	1.40 (1.02-1.92)	4.28	.04 <sup>c</sup>	.17
T-C-T	30.8	345.2	81.7	492.3	0.54 (0.35-0.83)	7.94	.005 <sup>c</sup>	.03 <sup>c</sup>
Patients with migraine without aura								
T-C-T	14.9	207.1	81.7	492.3	0.43 (0.24-0.77)	8.49	.004 <sup>c</sup>	.02 <sup>c</sup>
T-T-T	74.1	147.9	147.9	426.1	1.44 (1.03-2.02)	4.61	.03 <sup>c</sup>	.15

Abbreviations: CI, confidence interval; OR, odds ratio.

<sup>a</sup>rs3793243-rs941298-rs6951030.

<sup>b</sup>Only haplotypes with any significant result are shown.

<sup>c</sup>Nominal and corrected; significant value.

quency variation across populations; it may be more marked owing to gene  $\times$  gene and gene  $\times$  environment interactions.<sup>23</sup> This emphasizes the importance of replicating association studies in several populations.

Additionally, when pooling both samples, we found a significant effect of the T allele of rs941298 in migraineurs; this was expected, as the Catalanian study found significant results for this SNP and we saw an increased risk with the TT genotype in our sample. These results show that this SNP may be involved in susceptibility to migraine in both populations. More importantly, we found an increased risk with the G allele of rs6951030 in Portuguese migraineurs, which was not present in the pooled sample; we can postulate that the association with rs6951030 is specific to our population.

In FHM, glutamate release, facilitated by the mutated voltage-dependent calcium channel  $\alpha_{1A}$  subunit, results in cortical spreading depression (CSD), a slowly propagating wave of neuronal and glial depolarization, that moves through the cortex.<sup>24</sup> Cortical spreading depression is the underlying mechanism implicated in the visual, sensory, or motor aura observed in migraine with aura, during which several neurotransmitters are released.<sup>24</sup> In migraine without aura, imaging studies suggest that CSD may occur in silent brain areas, leading to

pain but not other symptoms.<sup>25,26</sup> The association of the SNARE proteins (including syntaxin 1A) with presynaptic  $Ca^{2+}$  channels, namely the voltage-dependent calcium channel  $\alpha_{1A}$  subunit, is essential for neurotransmitter release.<sup>11</sup> Therefore, polymorphisms in *STX1A* may alter the interaction between syntaxin 1A and calcium channels, modifying the functional state of the voltage-dependent calcium channel  $\alpha_{1A}$ , altering neurotransmitter release and, ultimately, contributing to CSD and the migraine phenotype.<sup>12,27</sup>

Although no functional role has yet been described for any of these intronic SNPs, it would be important to further evaluate that possibility. We found that both rs941298 and rs6951030, but also rs867500 (which is in LD with rs941298), are located in regions that are potentially important for regulation. Further analyses are needed to evaluate a potential functional role of these SNPs and understand their effect on syntaxin 1A.

Although our sample is not very large, we had special concern in obtaining a high case to control ratio—to increase power. Also, cases and controls were matched for age at observation and sex and were from the same geographic region (several studies, using markers sensitive to population stratification as lineage markers, have shown that there is no population substructure).

ture among the Portuguese population<sup>28-30</sup>). Also, we used corrections for multiple testing to prevent type I errors (Bonferroni and permutation-based corrections). We used logistic regression analyses to examine the SNPs' effects altogether.

In conclusion, our study favors and brings new insight into the involvement of syntaxin 1A in susceptibility to migraine and strengthens the role of neurotransmitter release in its pathophysiology. We can thus confirm the association between syntaxin 1A and migraine found in Catalanian patients. Additional studies with larger samples in other populations will be important to disentangle the role of this gene in migraine subtypes.

Accepted for Publication: August 17, 2009.

**Correspondence:** Alda Sousa, PhD, Department of Population Studies, Instituto Ciências Biomédicas Abel Salazar, University of Porto, 4099-003 Porto, Portugal (absousa@icbas.up.pt).

**Author Contributions:** The principal author had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. *Study concept and design:* Lemos, Alonso, and Sousa. *Acquisition of data:* Lemos, Pereira-Monteiro, Ramos, Barros, and Alonso. *Analysis and interpretation of data:* Lemos, Mendonça, Sequeiros, and Sousa. *Drafting of the manuscript:* Lemos, Mendonça, and Sousa. *Critical revision of the manuscript for important intellectual content:* Pereira-Monteiro, Mendonça, Ramos, Barros, Sequeiros, Alonso, and Sousa. *Statistical analysis:* Lemos, Mendonça, and Sousa. *Obtained funding:* Lemos, Pereira-Monteiro, and Sequeiros. *Administrative, technical, and material support:* Alonso. *Study supervision:* Pereira-Monteiro, Sequeiros, Alonso, and Sousa.

**Financial Disclosure:** None reported.

**Funding/Support:** This study was supported in part by grant POCTI-034390/99/FCT from the Fundação para a Ciência e Tecnologia, Sociedade Portuguesa de Cefaleias, and the National Headache Foundation (United States). Ms Lemos is the recipient of a Fundação para a Ciência e Tecnologia fellowship (SFRH/BD/17761/2004).

**Additional Contributions:** We would like to thank all patients and controls for participating in this study. Serafim Guimarães, MD, and nurses Teresa Gomes, BSc, and Palmira Gouveia, BSc, assisted with sample collection and Paula Magalhães, MSc, provided technical assistance.

## REFERENCES

1. Stovner LJ, Zwart JA, Hagen K, Terwindt GM, Pascual J. Epidemiology of headache in Europe. *Eur J Neurol*. 2006;13(4):333-345.
2. Bigal ME, Liberman JN, Lipton RB. Age-dependent prevalence and clinical features of migraine. *Neurology*. 2006;67(2):246-251.
3. Wessman M, Terwindt GM, Kaunisto MA, Palotie A, Ophoff RA. Migraine: a complex genetic disorder. *Lancet Neurol*. 2007;6(6):521-532.
4. Lemos C, Castro MJ, Barros J, et al. Familial clustering of migraine: further evidence from a Portuguese study. *Headache*. 2009;49(3):404-411.
5. Colson NJ, Fernandez F, Lea RA, Griffiths LR. The search for migraine genes: an overview of current knowledge. *Cell Mol Life Sci*. 2007;64(3):331-344.
6. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT<sub>1B/1D</sub>) agonists) in acute migraine treatment: a meta-analysis of 53 trials. *Lancet*. 2001;358(9294):1668-1675.
7. Nakamura K, Anitha A, Yamada K, et al. Genetic and expression analyses reveal elevated expression of syntaxin 1A (STX1A) in high functioning autism. *Int J Neuropsychopharmacol*. 2008;11(8):1073-1084.
8. Fan HP, Fan FJ, Bao L, Pei G. SNAP-25/syntaxin 1A complex functionally modulates neurotransmitter gamma-aminobutyric acid reuptake. *J Biol Chem*. 2006;281(38):28174-28184.
9. Meffert MK, Calakos NC, Scheller RH, Schulman H. Nitric oxide modulates synaptic vesicle docking fusion reactions. *Neuron*. 1996;16(6):1229-1236.
10. Olesen J. The role of nitric oxide (NO) in migraine, tension-type headache and cluster headache. *Pharmacol Ther*. 2008;120(2):157-171.
11. Jarvis SE, Zamponi GW. Interactions between presynaptic Ca<sup>2+</sup> channels, cytoplasmic messengers and proteins of the synaptic vesicle release complex. *Trends Pharmacol Sci*. 2001;22(10):519-525.
12. Corominas R, Ribases M, Cuenca-Leon E, et al. Contribution of syntaxin 1A to the genetic susceptibility to migraine: a case-control association study in the Spanish population. *Neurosci Lett*. 2009;455(2):105-109.
13. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. *Cephalalgia*. 1988;8(suppl 7):1-96.
14. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders, 2nd edition. *Cephalalgia*. 2004;24(suppl 1):9-160.
15. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. *Nucleic Acids Res*. 1988;16(3):1215.
16. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. *Bioinformatics*. 2005;21(2):263-265.
17. Terwilliger JD, Ott J. *Handbook of Human Genetic Linkage*. Baltimore, MD: The Johns Hopkins University Press; 1994.
18. Qin ZS, Niu T, Liu JS. Partition-ligation-expectation-maximization algorithm for haplotype inference with single-nucleotide polymorphisms. *Am J Hum Genet*. 2002;71(5):1242-1247.
19. Pereira Monteiro JM, Maio R, Calheiros JM. Overlap of migraine and tension-type headaches in a population-based study. In: Olesen J, ed. *Headache Classification and Epidemiology*. Vol 4. New York, NY: Raven Press; 1994:103-106.
20. Pereira Monteiro JM, Barros JR. Familial incidence of primary headaches in a general population. In: Olesen J, Bousser M-G, eds. *Genetics of Headache Disorders*. Vol 8. Philadelphia, PA: Lippincott-Williams & Wilkins; 2000:37-40.
21. Conde L, Vaquerizas JM, Dopazo H, et al. PupaSuite: finding functional single nucleotide polymorphisms for large-scale genotyping purposes. *Nucleic Acids Res*. 2006;34(Web server issue):W621-W625.
22. Kaminsky Z, Wang SC, Petronis A. Complex disease, gender and epigenetics. *Ann Med*. 2006;38(8):530-544.
23. Adeyemo A, Rotimi C. Genetic variants associated with complex human diseases show wide variation across multiple populations [published online ahead of print May 13, 2009]. *Public Health Genomics*. 2010;13:72-79.
24. Striessnig J. Pathophysiology of migraine headache: insight from pharmacology and genetics. *Drug Discov Today Dis Mech*. 2005;2(4):453-462.
25. Buzzi MG, Moskowitz MA. The pathophysiology of migraine: year 2005. *J Headache Pain*. 2005;6(3):105-111.
26. Sanchez-Del-Rio M, Reuter U, Moskowitz MA. New insights into migraine pathophysiology. *Curr Opin Neurol*. 2006;19(3):294-298.
27. Keith RK, Poage RE, Yokoyama CT, Catterall WA, Meriney SD. Bidirectional modulation of transmitter release by calcium channel/syntaxin interactions in vivo. *J Neurosci*. 2007;27(2):265-269.
28. Pereira L, Prata MJ, Amorim A. Diversity of mtDNA lineages in Portugal: not a genetic edge of European variation. *Ann Hum Genet*. 2000;64(pt 6):491-506.
29. Pereira R, Fondevila M, Phillips C, Amorim A, Carracedo A, Gusmao L. Genetic characterization of 52 autosomal SNPs in the Portuguese population. *Forensic Sci Int Genet*. 2008;1:358-360.
30. Beleza S, Gusmao L, Lopes A, et al. Micro-phylogeographic and demographic history of Portuguese male lineages. *Ann Hum Genet*. 2006;70(pt 2):181-194.

To date, CSF analyses have not been a routine component of assessment and care for patients with cognitive impairments and suspected AD in the United States. There is now ample evidence that these measurements have value; physicians need to formulate when and how to incorporate CSF measurements into their practice. We strongly recommend CSF analyses of A $\beta$ 1-42, T-tau, and P-tau in circumstances where having a definitive diagnosis of AD is important for counseling patients about such concerns as work, driving, and making other lifestyle changes. The CSF biomarkers will also improve accuracy for determining treatment in clinical situations where other conditions, such as normal-pressure hydrocephalus, depression, or vascular ischemic changes, figure in the differential diagnosis. There is already ample evidence that the AD CSF signature has a place in predicting which individuals with MCI are most at risk to progress to dementia, and it may even have value in predicting the rate of cognitive decline. The CSF analyses of A $\beta$ , T-tau, and P-tau should have a central place in experimental clinical trials to increase the likelihood that participants have AD and eliminate other diagnoses that might dilute treatment effects. Gazing into the future when there are neuroprotective medications for AD, we can envision a recommendation that CSF analyses be implemented as a screening test to identify clinically healthy individuals at risk for MCI and AD. The information gained would enable early application of treatments to delay onset of symptoms or slow progression of cognitive impairments.

A. Zara Herskovits, MD, PhD  
John H. Growdon, MD

**Author Affiliations:** Department of Pathology, Brigham and Women's Hospital (Dr Herskovits) and Department of Neurology, Massachusetts General Hospital (Dr Growdon), Boston, Massachusetts.

**Correspondence:** Dr Growdon, Department of Neurol-

ogy, Massachusetts General Hospital, Wang Ambulatory Care Center 729, Boston, MA 02114 (jgrowdon@partners.org).

**Financial Disclosure:** None reported.

## REFERENCES

1. De Meyer G, Shapiro F, Vanderstichele H, et al. Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. *Arch Neurol*. 2010;67(8):949-956.
2. Craig-Schapiro R, Fagan AM, Holtzman DM. Biomarkers of Alzheimer's disease. *Neurobiol Dis*. 2009;35(2):128-140.
3. Mattsson N, Zetterberg H, Hansson O, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. *JAMA*. 2009;302(4):385-393.
4. Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Consensus report of the working group on molecular and biochemical markers of Alzheimer's disease. *Neurobiol Aging*. 1998;19(2):109-116.
5. Tapiola T, Alafuzoff I, Herukka SK, et al. Cerebrospinal fluid  $\beta$ -amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. *Arch Neurol*. 2009;66(3):382-389.
6. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al; Alzheimer's Disease Neuroimaging Initiative. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. *Ann Neurol*. 2009;65(4):403-413.
7. Bacskai BJ, Frosch MP, Freeman SH, et al. Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. *Arch Neurol*. 2007;64(3):431-434.
8. Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid A $\beta$ <sub>42</sub> in humans. *Ann Neurol*. 2006;59(3):512-519.
9. Dubois B, Feldman H, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. *Lancet Neurol*. 2007;6(8):734-746.
10. Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/ $\beta$ -amyloid<sub>42</sub> ratio as a prediction of cognitive decline in nondemented older adults. *Arch Neurol*. 2007;64(3):343-349.
11. Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. *Lancet Neurol*. 2010;9(1):119-128.
12. Snider BJ, Fagan AM, Roe C, et al. Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. *Arch Neurol*. 2009;66(5):638-645.

## Correction

**Errors in Table.** In the article "Evidence of Syntaxin 1A Involvement in Migraine Susceptibility: A Portuguese Study," published in the April issue of the *Archives* (2010; 67[4]:422-427), there were a few errors in Table 3. In the rs941298 section of the table, the CC and TT genotype cells in the "All Patients With Migraine" column should be switched. The number and frequency for the TT genotype should be 28 (14.9%) and for the CC genotype, 86 (45.7%). The CC and TT genotype cells should also be switched in the "Controls" column: the number and frequency for the TT genotype should be 28 (9.8%) and for the CC genotype, 142 (49.5%).